← Browse by Condition
Medical Condition

unresectable digestive system neuroendocrine tumor g2

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT05773274 Phase 2
Recruiting

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Enrollment
100 pts
Location
United States, Canad...
Sponsor
National Cancer Institute (NCI...
View Trial →